Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard S Kaplan

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancerArnold L Potosky, Linda C Harlan, Richard S Kaplan, et al.
Neuro-Oncology|October 11, 2005
GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trialsSusan M Chang, Sharon L Reynolds, Nicholas Butowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2006
Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301Helen X Chen, Margaret Mooney, Matthew Boron, et al.
Trials|May 30, 2019
Mind the gap? The platform trial as a working environmentLiz Morrell, Joshua Hordern, Louise Brown, et al.
Cancer|September 19, 2002
The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysisJanet E Olson, Carol A Janney, Ravi D Rao, et al.
JCO Precision Oncology|February 9, 2022
Role for Nucleotide Excision Repair Gene Variants in Oxaliplatin-Induced Peripheral NeuropathyHannah West, Michelle Coffey, Michael J Wagner, et al.
Cancer|March 25, 2017
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trialDan P Stark, Adrian Cook, Julia M Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2018
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapyAyman Madi, David Fisher, Timothy S Maughan, et al.
Journal of Medical Genetics|March 12, 2017
Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximabAyman Madi, David Fisher, Timothy S Maughan, et al.
Gynecologic Oncology|November 20, 2018
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancerAntonio González Martín, Amit M Oza, Andrew C Embleton, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancerArnold L Potosky, Linda C Harlan, Richard S Kaplan, et al.
Neuro-Oncology|October 11, 2005
GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trialsSusan M Chang, Sharon L Reynolds, Nicholas Butowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2006
Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301Helen X Chen, Margaret Mooney, Matthew Boron, et al.
Trials|May 30, 2019
Mind the gap? The platform trial as a working environmentLiz Morrell, Joshua Hordern, Louise Brown, et al.
Cancer|September 19, 2002
The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysisJanet E Olson, Carol A Janney, Ravi D Rao, et al.
JCO Precision Oncology|February 9, 2022
Role for Nucleotide Excision Repair Gene Variants in Oxaliplatin-Induced Peripheral NeuropathyHannah West, Michelle Coffey, Michael J Wagner, et al.
Cancer|March 25, 2017
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trialDan P Stark, Adrian Cook, Julia M Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2018
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapyAyman Madi, David Fisher, Timothy S Maughan, et al.
Journal of Medical Genetics|March 12, 2017
Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximabAyman Madi, David Fisher, Timothy S Maughan, et al.
Gynecologic Oncology|November 20, 2018
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancerAntonio González Martín, Amit M Oza, Andrew C Embleton, et al.
Pageof 3